The time has come for me to bid farewell to readers of my column. I took some time off from writing to reflect on my purpose, spend time with my growing family, and focus on my health. I can’t thank Bionews, the parent company of this website, enough for…
Read more
Six months of twice-daily treatment with oral Fabhalta (iptacopan) improved hemoglobin levels in adults with paroxysmal nocturnal hemoglobinuria (PNH) who switched from standard anti-C5 therapies, according to top-line results from a Phase 3 clinical trial. Dubbed APPULSE-PNH (NCT05630001), the now-complete study tested Novartis’ therapy in 52…
In December, I always reflect on the year that’s passed and find myself saying “I can’t believe I made it to the end of the year” or “What a year it’s been.” It’s as if a light bulb is going out, and I realize the year will soon be a…
Note: This story was updated Dec. 6, 2024, to correct that Voydeya is approved as an add-on treatment to standard PNH therapies to help control extravascular hemolysis. The headline was changed to clarify that these were the results of a review study. Voydeya (danicopan) — whether given as a…
Get regular updates delivered to your inbox.
